Related Experiment Video

Updated: Jul 3, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

A Brain-Targeted DNA Delivery Nanocarrier Modulator for Synergistic Therapy of Parkinson's Disease

Yuxue Cheng1, Limin Zhai1, Haoyuan Wang1

  • 1School of Life Sciences, South China Normal University, Guangzhou 510631, China.

ACS Applied Materials & Interfaces
|July 2, 2026
PubMed

Insights

This study introduces a novel nanoparticle system for Parkinson's Disease (PD) therapy. The borneol-modified nanoparticles effectively deliver multiple therapeutic agents, reducing neuronal damage and improving motor function in a PD mouse model.

Area of Science:

  • Neuroscience
  • Nanotechnology
  • Pharmacology

Background:

  • Parkinson's Disease (PD) pathology is complex, involving alpha-synuclein aggregation, mitochondrial dysfunction, and oxidative stress.
  • Multitarget therapeutic strategies are crucial for effective PD intervention.

Purpose of the Study:

  • To develop a borneol-modified carboxymethyl chitosan nanoparticle system (BC/P/HCR NPs) for codelivering curcumin, rosmarinic acid, and pDNA targeting the SNCA gene.
  • To evaluate the therapeutic efficacy of BC/P/HCR NPs in a mouse model of PD.

Main Methods:

  • Development of BC/P/HCR NPs for simultaneous delivery of curcumin, rosmarinic acid, and SNCA-targeting pDNA.
  • Administration of BC/P/HCR NPs in a C57BL/6 mouse model of PD.
  • Assessment of BBB penetration, motor function, neuronal damage, alpha-synuclein expression, mitochondrial function, and oxidative stress.

Main Results:

  • BC/P/HCR NPs demonstrated enhanced blood-brain barrier (BBB) penetration.
  • Significant alleviation of motor dysfunction and reduction in neuronal damage were observed.
  • Downregulation of alpha-synuclein expression, restoration of mitochondrial function, and mitigation of oxidative stress were achieved.

Conclusions:

  • BC/P/HCR NPs show potential as a multifunctional nanotherapeutic platform for PD.
  • The codelivery system effectively addresses multiple pathological hallmarks of Parkinson's Disease.
  • Borneol enhances BBB permeability, while carboxymethyl chitosan improves drug solubility and controls release.
Keywords:
blood-brain barrier (BBB)borneolgene therapynanoparticlesparkinson’s diseasesynergistic therapy

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.